[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100649995":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":11,"centralContacts":23,"locations":29,"responsibleParty":49,"collaborators":11,"id":51,"slug":52,"hasResults":53,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":11,"eligibilityCriteria":57,"healthyVolunteers":53,"sex":58,"minAge":59,"maxAge":11,"enrollmentInfo":60,"targetDuration":11,"studyType":63,"phases":64,"briefSummary":66,"conditions":67,"keywords":11,"overallStatus":32,"whyStopped":11,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":78},{"fullName":5,"class":6},"Second Affiliated Hospital, School of Medicine, Zhejiang University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"TEER + Electrical Cardioversion","EXPERIMENTAL",null,[13],"Procedure: TEER and Electrical Cardioversion",{"label":15,"type":16,"description":11,"interventionNames":11},"TEER Alone","NO_INTERVENTION",[18],{"type":19,"name":20,"description":21,"armGroupLabels":22,"otherNames":11},"PROCEDURE","TEER and Electrical Cardioversion","Transcatheter Edge-to-Edge Repair (TEER) followed by immediate electrical cardioversion (ECV) during the same procedure. ECV is performed with synchronized shock at 100-200J, preceded by intravenous amiodarone 300mg. If the first shock fails, a repeated shock up to 200J may be attempted. All patients receive guideline-directed medical therapy (GDMT), anticoagulation, and antiarrhythmic drugs per standard practice.",[9],[24],{"name":25,"role":26,"phone":27,"phoneExt":11,"email":28},"Jianan Wang","CONTACT","0571-87784804","wangjianan111@zju.edu.cn",[30],{"facility":31,"status":32,"city":33,"state":34,"zip":35,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"The Second Affiliated Hospital Zhejiang University School of Medicine","RECRUITING","Hangzhou","Zhejiang","310009","China","CN",{"type":39,"coordinates":40},"Point",[41,42],120.16142,30.29365,{"lat":42,"lon":41},[45],{"name":46,"role":26,"phone":47,"phoneExt":11,"email":48},"Yaping Wang","86-13805725837","yapingwang@zju.edu.cn",{"type":50,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100649995","a-study-on-the-efficacy-and-safety-of-teer-combined-with-electrical-cardioversion-in-patients-with-severe-mitral-regurgitation-and-atrial-fibrillation-100649995",false,"NCT07741383","A Study on the Efficacy and Safety of TEER Combined With Electrical Cardioversion in Patients With Severe Mitral Regurgitation and Atrial Fibrillation","A Study on the Efficacy and Safety of TEER Combined Electrical Cardioversion in Patients With Severe Mitral Regurgitation and Atrial Fibrillation: A Prospective, Multicenter, Open-Label Randomized Controlled Study","Inclusion Criteria:\n\n1. Age ≥ 18 years;\n2. Successful TEER procedure with residual mitral regurgitation grade \\\u003C 2+;\n3. No left atrial thrombus, no severe cardiomyopathy, left atrial anteroposterior diameter \\\u003C 5.5 cm, and anatomically suitable for electrical cardioversion;\n4. Ability to understand the study objectives, voluntarily sign the informed consent form, and willingness to comply with required examinations and clinical follow-up.\n\nExclusion Criteria:\n\n* 1\\. Left ventricular ejection fraction \\\u003C 20%; 2. Stroke or transient ischemic attack within 30 days; 3. Contraindication to anticoagulants, antiplatelet agents, or antiarrhythmic drugs; 4. Severe diseases that may interfere with treatment evaluation, such as severe neurological impairment affecting cognitive function, malignant tumors, etc.; 5. Life expectancy \\\u003C 12 months; 6. Any other anatomical, concomitant disease, medical, social, or psychological condition that, in the investigator's judgment, may limit the participant's ability to comply with study requirements or affect the scientific validity of the study results.","ALL","18 Years",{"count":61,"type":62},570,"ESTIMATED","INTERVENTIONAL",[65],"NA","This study aims to evaluate the safety and efficacy of combined electrical cardioversion and TEER in patients with severe mitral regurgitation and atrial fibrillation after undergoing TEER. The main objective is to assess the superiority of the combined treatment strategy in reducing the composite endpoints of all-cause mortality, re-hospitalization for heart failure, and stroke within one year, providing high-quality evidence-based medical evidence to optimize the \"structural repair + rhythm control\" comprehensive intervention strategy for such patients.",[68],"Atrial Fibrillation Mitral Valve Insufficiency","2026-07-29",{"date":71,"type":72},"2026-08-03","ACTUAL",{"date":74,"type":72},"2026-07-14",{"date":76,"type":62},"2029-12-31",{"name":5,"class":6},1]